TCHB.F Stock Overview
Provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Tecan Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 218.79 |
| 52 Week High | CHF 400.00 |
| 52 Week Low | CHF 208.03 |
| Beta | 0.74 |
| 1 Month Change | 5.17% |
| 3 Month Change | n/a |
| 1 Year Change | -44.38% |
| 3 Year Change | -45.81% |
| 5 Year Change | -27.67% |
| Change since IPO | 623.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCHB.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -0.4% |
| 1Y | -44.4% | -14.6% | 20.8% |
Return vs Industry: TCHB.F underperformed the US Life Sciences industry which returned -14.4% over the past year.
Return vs Market: TCHB.F underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| TCHB.F volatility | |
|---|---|
| TCHB.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TCHB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine TCHB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 3,000 | Achim von Leoprechting | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and antibodies, and software; and Tecan Labwerx, an automation solution.
Tecan Group AG Fundamentals Summary
| TCHB.F fundamental statistics | |
|---|---|
| Market cap | US$2.95b |
| Earnings (TTM) | US$112.88m |
| Revenue (TTM) | US$1.11b |
26.1x
P/E Ratio2.6x
P/S RatioIs TCHB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCHB.F income statement (TTM) | |
|---|---|
| Revenue | CHF 1.00b |
| Cost of Revenue | CHF 653.34m |
| Gross Profit | CHF 346.71m |
| Other Expenses | CHF 245.37m |
| Earnings | CHF 101.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 12, 2025
| Earnings per share (EPS) | 7.90 |
| Gross Margin | 34.67% |
| Net Profit Margin | 10.13% |
| Debt/Equity Ratio | 17.8% |
How did TCHB.F perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield38%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 13:16 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecan Group AG is covered by 21 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Mayer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Scott Bardo | Berenberg |